Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and indolent systemic mastocytosis. From Wikipedia
Securing Ayvakit licensing reinforces Sanofi’s bid to dominate immunology with a focus on rare diseases
